Home Cart Sign in  
Chemical Structure| 1949837-12-0 Chemical Structure| 1949837-12-0

Structure of ARV-771
CAS No.: 1949837-12-0

Chemical Structure| 1949837-12-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ARV-771 is an efficient, selective, orally bioavailable androgen receptor (AR) degrading PROTAC. It inhibits AR-related tumor growth by binding to the androgen receptor and promoting its degradation. ARV-771 has demonstrated significant research potential in treating various prostate cancers, including metastatic castration-resistant prostate cancer.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Chen, Jing ; Ji, Peng ; Gnawali, Giri ; Chang, Mengyang ; Gao, Feng ; Xu, Hang , et al.

Abstract: The current targeting drug delivery mainly relies on cancer cell surface receptors. However, in many cases, binding affinities between protein receptors and homing ligands is relatively low and the expression level between cancer and normal cells is not significant. Distinct from conventional targeting strategies, we have developed a general cancer targeting platform by building artificial receptor on cancer cell surface via a chemical remodeling of cell surface glycans. A new tetrazine (Tz) functionalized chemical receptor has been designed and efficiently installed on cancer cell surface as "overexpressed" biomarker through a metabolic glycan engineering. Different from the reported bioconjugation for drug targeting, the tetrazine labeled cancer cells not only locally activate TCO-caged prodrugs but also release active drugs via the unique bioorthogonal Tz-TCO click-release reaction. The studies have demonstrated that the new drug targeting strategy enables local activation of prodrug, which ultimately leads to effective and safe cancer therapy.

Keywords: Artificial receptor ; Click and release ; Local activation ; Protein degradation

Alternative Products

Product Details of ARV-771

CAS No. :1949837-12-0
Formula : C49H60ClN9O7S2
M.W : 986.64
SMILES Code : O=C([C@H]1N(C([C@H](C(C)(C)C)/N=C(O)/COCCCOCCNC(C[C@H]2C3=NN=C(C)N3C4=C(C(C)=C(C)S4)C(C5=CC=C(Cl)C=C5)=N2)=O)=O)C[C@H](O)C1)N[C@H](C6=CC=C(C7=C(C)N=CS7)C=C6)C
MDL No. :MFCD30738017
InChI Key :PQOGZKGXGLHDGS-QQRWPDCKSA-N
Pubchem ID :126619980

Safety of ARV-771

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of ARV-771

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-436 0.45 µM 4 days Inhibited cell growth and migration, mainly affected cytokines and their receptors PMC11452555
H460 5 µM Inhibited radiation-induced and cisplatin-induced tumour cell surface PD-L1 expression PMC8792480
A549 5 µM Inhibited radiation-induced and cisplatin-induced tumour cell surface PD-L1 expression PMC8792480
A549 cells 50 and 100 nM 16 hours Induced degradation of BRD4 protein PMC11227109
VCaP cells <5 nM 16 hours ARV-771 effectively degrades BRD2/3/4 proteins in VCaP cells with a DC50 value <5 nM PMC4932933
22Rv1 cells <5 nM 16 hours ARV-771 effectively degrades BRD2/3/4 proteins in 22Rv1 cells with a DC50 value <5 nM PMC4932933
RH41 cells 297.7 nM (IC50) 120 hours Assessed cell proliferation inhibition, ARV-771 had an IC50 of 297.7 nM, showing higher potency than JQ1 PMC9966215
LnCaP95 cells <5 nM 16 hours ARV-771 effectively degrades BRD2/3/4 proteins in LnCaP95 cells with a DC50 value <5 nM PMC4932933
B16F10 cells 10, 20, 50, 100, 200 nM 24 hours Evaluate the effect of ARV@PDSA on BRD4 protein degradation, showing that ARV@PDSA degrades BRD4 more effectively than free ARV-771 at low concentrations. PMC10238184
HeLa cells 10, 20, 50, 100, 200 nM 24 hours Evaluate the effect of ARV@PDSA on BRD4 protein degradation, showing that ARV@PDSA degrades BRD4 more effectively than free ARV-771 at low concentrations. PMC10238184
HCCLM3 0.5 μM 24 hours To evaluate the effect of ARV-771 on HCC cell viability, results showed that ARV-771 dose-dependently inhibited HCC cell viability. PMC9114478
Hep3B 0.25 μM 24 hours To evaluate the effect of ARV-771 on HCC cell viability, results showed that ARV-771 dose-dependently inhibited HCC cell viability. PMC9114478
HepG2 0.5 μM 24 hours To evaluate the effect of ARV-771 on HCC cell viability, results showed that ARV-771 dose-dependently inhibited HCC cell viability. PMC9114478
BH1406 cells 10 μM 4 days Evaluate the growth inhibitory effect of ARV-771 on BH1406 cells, showing that ARV-771 significantly inhibited the growth of BH1406 cells and had synergistic effects with BAY-293. PMC11632420
MDA-MB-231 0.12 µM 4 days Inhibited cell growth and migration, significantly reduced expression of ERBB family receptors PMC11452555
RH4 cells 100 nM 6 hours Assessed BRD4 degradation efficacy, immunofluorescence showed near-complete removal of BRD4 from the cell nucleus PMC9966215

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice HeLa tumor model Intravenous injection 3 mg/kg and 10 mg/kg Every other day for 12 days Evaluate the anti-tumor efficacy of ARV@PDSA in vivo, showing significant tumor growth inhibition, BRD4 degradation, and c-Myc downregulation. PMC10238184
Nu/Nu mice 22Rv1 tumor xenograft model Subcutaneous injection 10 mg/kg Once daily for 3 days ARV-771 significantly reduces BRD4 and c-MYC levels and induces tumor regression in the 22Rv1 tumor xenograft model PMC4932933
SCID mice A549 xenograft model Intraperitoneal injection 20 mg/kg 5 days ON/2 days OFF for 19 days Significantly inhibited tumor growth without observable toxicity PMC11227109
Nude mice HepG2 xenograft model Intraperitoneal injection 20 mg/kg Every other day for 25 days To evaluate the inhibitory effect of ARV-771 on HCC progression in vivo, results showed that ARV-771 significantly inhibited tumor growth. PMC9114478

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.01mL

0.20mL

0.10mL

5.07mL

1.01mL

0.51mL

10.14mL

2.03mL

1.01mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories